Sartorius

行业

生物工艺设备, 工业化学

主题

合成生物学平台与生物制造

角色

生产商 — “…rug discovery to commercial manufacturing. Key points: - Mission: Simplify progress in the bio-century by tran…”

为何属于生物经济

Sartorius是生物反应器、发酵设备和生物工艺解决方案的全球主要供应商，服务于制药和生物技术行业。

产品: Octet® R2 BLI System; Octet® R4 BLI System; Octet® R8 BLI System; Octet® R8e BLI System - NEW; Octet® RH16 BLI System; Octet® RH96 BLI System; Octet® N1 BLI System; Octet® AS BLI System; Octet® BLI GxP Compliance Tools; Octet® BLI Biosensors & Kits

生产与研发基地 3

• Göttingen, Germany Sartorius AG
• Aubagne
• Aubagne, France

来自公司网站及自动化调研的生产、研发等基地；不含街道地址。

应用

Biopharmaceutical labs · Chemical labs · Food labs · Academic labs · Life Science Research · Basic Research

产品（官网）

Octet® R2 BLI System · Octet® R4 BLI System · Octet® R8 BLI System · Octet® R8e BLI System - NEW · Octet® RH16 BLI System · Octet® RH96 BLI System · Octet® N1 BLI System · Octet® AS BLI System · Octet® BLI GxP Compliance Tools · Octet® BLI Biosensors & Kits · Octet® BLI Automation & Integration · Incucyte® CX3 System

摘自公司官网: about · products · production · quality · rnd · leadership · contact · sustainability

子公司: Sartorius Stedim Biotech S.A. (71.5% stake) · Sartorius Lab Holding GmbH (100% stake)

• 2026-06 最新状态: 2026年上半年，公司收购了子公司 Sartorius CellGenix GmbH 剩余 24% 的股权。 ↗ ↗ ↗

近期新闻 5

由自动检索获得；摘要为机器生成的英文。标题含公司名称，或摘要以该公司为主体——引用前请核对原文。

• 2026-10-04 Sartorius stock reports 7.7 percent H1 sales growth ad-hoc-news.de
  Sartorius posted 7.7% organic H1 2026 sales growth with a 30.3% underlying EBITDA margin, signaling solid execution and a favorable margin framework ahead of the Q3 results. The company maintains guidance for 2026 (5–9% sales growth in constant currencies and margin above 30%), …
• 2026-09-16 Sartorius and NIBRT announce partnership: Pioneering dedicated training center for intensified and continuous bioprocessing sartorius.com
  Sartorius is expanding its leadership in bioprocessing by partnering with NIBRT to create a premier training center in Dublin for intensified and fully continuous manufacturing, featuring its end-to-end Pionic platform to train thousands of scientists and engineers annually. The …
• 2026-07-23 Sartorius setzt positive Dynamik fort und wächst weiter profitabel sartorius.com
  Sartorius continues a positive trajectory in H1 2026 with robust, currency-adjusted growth of 7.7% in operative revenue, supported by recurring consumables, and an improved EBITDA margin of 30.3%; the company confirms its full-year 2026 guidance, expecting around 5–9% …
• 2026-05-21 Sartorius opens new competence center for cell and gene therapy components in Freiburg, Germany sartorius.com
  Sartorius is expanding its commitment to cell and gene therapy by opening a new, sustainable competence center in Freiburg, Germany, investing over €140 million to boost GMP-compliant production of quality-critical materials (cytokines, growth factors, media) and nearly doubling …
• 2026-05-21 Sartorius eröffnet neues Kompetenzzentrum für Zell- und Gentherapie ‑Komponenten in Freiburg sartorius.com
  Sartorius eröffnet in Freiburg ein neues Kompetenzzentrum für die Entwicklung und Produktion qualitätskritischer Materialien für Zell- und Gentherapien, investiert über 140 Mio. Euro und verdoppelt die Kapazitäten. Das 18.000 m² große Facility, das vollständig ohne fossile …

股权与投资方 4

合作与交易 1

同类企业

Applikon Biotechnology · Bioengineering AG · BIONET · TECNIC Bioprocess Solutions · Bilfinger Life Science · bbi-biotech GmbH · Kbiotech GmbH · CerCell A/S

注册编号

• WKN: 716 563 (Preference Shares)
• ISIN: DE0007165631 (Preference Shares)
• WKN: 716 560 (Ordinary Shares)
• ISIN: DE0007165607 (Ordinary Shares)

融资

• 最近一轮: Post ipo debt · 2026-05-01 · US$ 587.4 M
• 累计融资: US$ 3.8 B

来自自动化调研（公司网站、公告、商业企业数据库），未经人工核对。注册编号请以官方登记为准。